DIABETES CARE
hamburger
INNOVATION

REAL-WORLD EVIDENCE PUBLICATIONS

SCIENTIFIC INSIGHTS GENERATED FROM MILLIONS OF FREESTYLE LIBRE USERS

 

 

 

 

Abbott has collaborated on multiple important scientific publications using real-world data from its FreeStyle Libre platform.

FreeStyle Libre data that Abbott has de-identified and anonymized to comply with Abbott’s privacy policies and data protection laws, is used for research to help advance scientific discoveries and create meaningful innovations for people with diabetes. These insights are shared at global scientific healthcare conferences, published in peer-reviewed journals, and used to improve clinical standards and care.

A selection of scientific manuscripts that have analyzed FreeStyle Libre user data are linked below:

2022

  • Frequency of flash glucose monitoring and glucose metrics: real-world observational data from Saudi Arabia 

    Journal: Diabetology & Metabolic Syndrome 

    Summary: This real-world data study analyzed glucose metrics from FreeStyle Libre in relation to scanning frequency, time in range (TIR) and estimated A1c (eA1c) in Saudi Arabia.  Read More

    The data set for Saudi Arabia included 6097 readers, 35,747 sensors, and 40 million automatic glucose measurements. Higher scanning frequency in flash glucose users from Saudi Arabia is associated with lower eA1c, higher TIR, lower glucose variability and less time in hypoglycemia or hyperglycemia. 


2021

  • Flash Glucose Monitoring in the Netherlands: Increased monitoring frequency is associated with improvement of glycemic parameters

    Journal: Diabetes Research and Clinical Practice 

    Details: Cited by multiple articles, including 2022 ADA Standards of Care

    Summary: The aim of the study was to evaluate the use of FLASH under real-life circumstances in the Netherlands and to assess the effects on glycemic parameters.  Read More

    Data comprising 16,331 readers (163,762 sensors) were analyzed. Increasing scan rates were associated with more time in range, less time in hyperglycemia, and a lower standard deviation of glucose. These outcomes among Dutch FLASH users suggest that with higher scan rate glycemic control improves.

  • Comparison of Glucose Metrics Between Users of CGM Readers and CGM-Connected Apps. Journal of Diabetes Science and Technology

    Journal: Journal of Diabetes Science and Technology

    Summary: This retrospective analysis compared glucose metrics of FreeStyle Libre 14-day users in the United States (14,000 users of the FreeStyle LibreLink app and 14,000 users of the FreeStyle Libre 14-day reader).  Read More

    Data from the Polish population were collected from 10,679 readers and 92,627 sensors. The worldwide database included information from 981,876 readers and 11,179,229 sensors. On average, the users of isCGMS from Poland achieved lower estimated HbA1c, spent more time in range, and less time-above-range. The analyzed glucometrics improved as the scan rate frequency increased. The data also show that in real-life practice, a large number of patients may be willing to perform scanning more frequently than is usually assumed.

  • Real-World Flash Glucose Monitoring in Argentina

    Journal: Revista Argentina de Endocrinología y Metabolismo

    Summary: The goal of this work was to examine the usage of flash glucose monitoring in a developing country such as Argentina and its association with glycemic markers.  Read More

    App users experienced lower glucose variability, lower average glucose, less time in hyperglycemia, and greater time in range than reader users. The observed differences may be driven by the data sharing features inherent in the app. By sharing glucose data with one’s clinical team, healthcare professionals and patients may be able to make more informed treatment decisions. 


2020

  • Real-world flash glucose monitoring in Brazil: can sensors make a difference in diabetes management in developing countries?

    Journal: Diabetology & Metabolic Syndrome 

    Details: Cited by multiple articles

    Summary: No previous studies had investigated the comparative effect of sensor-based monitoring on glycemic markers in developing countries like Brazil.  Read More

    The data comprised 688,640 readers and 7,329,052 sensors worldwide and included 17,691 readers and 147,166 sensors from Brazil. Similar to previous analyses, increased scan frequency was associated with better glycemic control – in this case, lower estimated HbA1c, lower time in hyperglycemia, and more time in range. 

  • Flash glucose monitoring reduces glycemic variability and hypoglycemia: real-world data from Spain

    Journal: BMJ Open Diabetes Research & Care

    Details: Cited by over 30 articles

    Summary: In this study, Spain-specific relationships between testing frequency and glycemic parameters were investigated under real-world settings.  Read More

    Spanish users (n=22,949) collected 37.1 million glucose scans and checked glucose values via a mean of 13 scans/day. High scan rates were associated with the favorable glycemic markers of increased time-in-range and reduced time in hyperglycemia and hypoglycemia, and glucose variability


2019

  • Flash Glucose Monitoring Improves Glycaemia in Higher Risk Patients: A Longitudinal, Observational Study under Real Life Settings

    Journal: BMJ Open Diabetes Research & Care

    Details: Cited by over 15 articles

    Summary: This analysis assessed the role of flash glucose monitoring in early and late changes in glycemic markers under real-life conditions.  Read More

    De-identified glucose results from 6,802 users with at least six months of data were analyzed after dividing into high, medium and low-risk groups based on time spent in hypoglycemia or hyperglycemia. The analysis determined that under real-world conditions, flash monitoring was associated with rapid and sustained reduction in dysglycemia with high-frequency scanners demonstrating more significant reduction in hyperglycemia. 


2018

  • Real-world flash glucose monitoring patterns and associations between self-monitoring frequency and glycaemic measures: A European analysis of over 60 million glucose tests

    Journal: Diabetes Research and Clinical Practice 

    Details: Cited by over 150 articles

    Summary: This was the first manuscript to analyze real-world data from FreeStyle Libre users to investigate the use of the system in real life clinical practice.  Read More

    Over 50,000 readers were included and over 90% of the data was from the seven initial FreeStyle Libre launch countries. Users performed an average of 16.3 glucose scans per day, almost four times more than average daily blood glucose checks previously reported. Higher scanning frequency was associated with better glycaemic measures including lower estimated HbA1c, decreased time in hyper and hypoglycemia and increased time in euglycemia with reduction in hypoglycemic exposure.

ADC-56426 Ver 1.0 06/22

YOU ARE ABOUT TO LEAVE FOR A 3RD PARTY WEBSITE

The "Yes" link below will take you out of the Abbott Laboratories family of websites. Links which take you out of Abbott Laboratories worldwide web sites are not under the control of Abbott Laboratories, and Abbott Laboratories is not responsible for the contents of any such site or any further links from such site. Abbott Laboratories is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott Laboratories.

DO YOU WISH TO LEAVE THIS SITE?

YOU ARE ABOUT TO EXIT THE ABBOTT FAMILY OF WEBSITES FOR A 3RD PARTY WEBSITE

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott. The website that you have requested also may not be optimized for your screen size.

DO YOU WISH TO CONTINUE AND EXIT THIS WEBSITE?

true
accessibility

NO

accessibility

YOU ARE ABOUT TO EXIT THE ABBOTT FAMILY OF WEBSITES FOR A 3RD PARTY WEBSITE

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott. The website that you have requested also may not be optimized for your screen size.

DO YOU WISH TO CONTINUE AND EXIT THIS WEBSITE?

accessibility

YOU ARE ABOUT TO LEAVE FOR A 3RD PARTY WEBSITE

The "Yes" link below will take you out of the Abbott Laboratories family of websites. Links which take you out of Abbott Laboratories worldwide web sites are not under the control of Abbott Laboratories, and Abbott Laboratories is not responsible for the contents of any such site or any further links from such site. Abbott Laboratories is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott Laboratories.

DO YOU WISH TO LEAVE THIS SITE?